“The DDD challenge has allowed us to enter into the field of research in a completely unforeseen way: by developing an innovative research project from A to Z around a biology-chemistry collaboration, and combining the themes of our respective laboratories. Our project relates to the use of bioconjugated antibodies with the aim of developing a new therapeutic tool targeting glioblastoma stem cells. This experience allowed us to collaborate with stakeholders in the academic and private sectors and thus to see beyond basic research objectives thanks to the idea of technology transfer.”